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Obesity is currently an epidemic and confers a more aggressive and often treatment-
resistant phenotype. There have been proposed mechanisms of obesity-induced breast 
cancer progression, however, it is still a continually active area of research with many 
more questions to be answered. The fatty acid synthase enzyme (FASN) has been an 
“Achilles Heel” for cancer, considering the large number of tumors that overexpress the 
enzyme. Inhibitors targeting FASN have been an active area of preclinical research over 
the past decade, with one, TVB-2640,  that is currently in clinical trials. We previously 
recorded an upregulation in FASN when breast cancer cells were exposed to obese 
sera compared to breast cancer cells exposed to lean sera, highlighting FASN 
expression as a possible mechanism behind obesity-induced breast cancer 
progression. We chose to investigate the role of the Insulin-like growth factor receptor 
(IGF-1R), which is also upregulated in many aggressive and resistant cancers, as a 
target of FASN. We hypothesis that the FASN is inducing breast cancer aggression 
through the increased localization and activation of the IGF-1R to the membrane. To 
visualize if the IGF-1R was localized as a target of FASN upregulation, we used the 
FASN inhibitor, TVB-3166. MCF-7, luminal A, and MD-MB-231, triple-negative, cells 
were treated with obese sera, insulin-like growth factor -1 (IGF-1), or lean sera. Cells 
vii 
were then either treated with the FASN inhibitor, TVB -3166 or the vehicle control 
(DMSO) for 72 hours and visualized for localization with immunofluorescence. 
Upon FASN inhibition treatment, the localization of the IGF-1R the membrane was 
abrogated compared to the control. These results highlight a potential mechanism in 
which IGF-1 induced localization of the IGF-1R is mediated through FASN. In summary, 
FASN highlights a potential therapeutic target in obesity-induced breast cancer with our 
lab previously demonstrating an accentuated FASN expression in response to obese 
sera exposure. Also, when FASN is targeted using the FASN inhibitor, TVB-3166, there 
is a consequential decrease in the IGF-1R localization in response to obese sera and 
IGF-1, Thus, FASN is a potential target in obesity-induced breast cancer and could 
participate in tumor progression through IGF-1R localization. 
viii
Table of Contents 
Table of Figures ................................................................................................................................. IX 
Chapter 1: Introduction .................................................................................................................... 1 
1.1 Breast Cancer Epidemiology and Classification ..................................................... 1 
1.2 Obesity and Breast Cancer ....................................................................................... 2 
1.3 The IGF-1 System ...................................................................................................... 6 
1.4 Fatty Acid Synthase ................................................................................................ 13 
Chapter 2: Insulin-like Growth Factor Receptor as a Target of FASN Modulation in 
Obesity- Induced Breast Cancer .................................................................................................. 18 
2.1 Abstract .................................................................................................................... 18 
2.2 Introduction ............................................................................................................. 19 
2.3 Methods.................................................................................................................... 21 
2.4 Results ..................................................................................................................... 23 
2.5 Discussion ............................................................................................................... 24 
Chapter 3: Concluding Remarks and Future Directions ....................................................... 27 
3.1 Conclusion ............................................................................................................... 27 
3.2 Future Directions ..................................................................................................... 27 
ix 
Table of Figures 
Figure 1. Obese Adipose Tissue ............................................................................................ 5 
Figure 2. Insulin-like Growth Factor Receptor ................................................................. 11 
Figure 3. RTK Downstream Signalling ............................................................................... 12 
Figure 4. de novo Lipogenesis ............................................................................................. 15 
Figure 5 (A-B): FASN Inhibition Abrogates IGF-1R Membrane Localization ........... 25 
1 
Chapter 1: Introduction 
1.1 Breast Cancer Epidemiology and Classification 
EPIDEMIOLOGY 
With the sobering epidemiological data, resulting in 41,760 deaths per year, breast 
cancer has become an unfortunate prevalence (1, 2). Due to its heterogeneity, breast 
cancer is not simply one cancer, but a multitude of differing subtypes, each with unique 
responses to therapies  (1, 3, 4). To aid in the identification and treatment of the breast 
carcinomas, various histological and molecular subclassifications have been 
established. Moreover, various risk factors can lead to cancer such as those found in 
the study conducted by Engmann et al. (5), that analyzed nearly 203,000 women for 
common risk factors associated with their cancer (5).  There was an astonishing 44 % of 
breast cancer estimated to attributed to risk factors such as breast density, family 
history and body mass index (BMI) in both pre and postmenopausal women (5). Other 
established risk factors that can drive these epigenetic and genetic alterations that lead 
to cancer include alcohol intake, diet, weight, hormone use and external environmental 
exposures (6). 
HISTOLOGICAL & MOLECULAR CLASSIFICATION OF BREAST CANCER 
The mammary tissue is a heterogeneous mix of epithelial and mesenchymal cells that 
include adipocytes, fibroblasts, endothelial cells, and immune cells (1, 7). The two main 
cell types within a mature mammary gland include luminal and basal myoepithelial cells. 
These two cells can undergo further differentiation into ductal cells or milk-producing 




subtypes of breast cancer, which can aid in proper treatment based on certain 
characteristics. For instance, the presence 
of the hormone receptor, estrogen receptor (ER), is used to classify subtypes and aid in 
targeted treatment (1, 8). Also, the human epidermal growth factor receptor-2 (HER-2), 
is used to classify subtypes of carcinomas (1). These can be used in combination with 
other molecular markers such as progesterone receptor (PgR) and the ki67 marker of 
proliferation (1, 8). Based on the expression of these markers or lack thereof, 
subclassifications have been named based on the origin of the lesion and expression of 
various receptors and proteins. The molecular subtypes of breast cancer include: 
Luminal A (estrogen receptor-positive), luminal B (estrogen receptor-positive and either 
HER2 positive or negative), HER2 enriched (expressed HER2), basal-like (estrogen and 
progesterone receptor negative) and claudin- low or mesenchymal- like (1, 8-10).    




Obesity is currently affecting 30 % of the United States (11). In addition to diabetes and 
cardiovascular disease, obesity has been associated with a higher risk of carcinomas of 
the esophagus, gastric, thyroid, pancreas, colorectal, endometrium, prostate, 
gallbladder, and breast (12). The risks for premenopausal women and breast cancer as 
well as triple-negative breast cancer has mixed results from various studies showing 
both positive and inverse correlations with breast cancer risk and BMI (11). Moreover, 
obese, postmenopausal women have a 30 % higher chance of developing breast 
cancer and are positively associated with each 5 kg/m2 unit of BMI increase (11). In 




recurrence as well as greater mortality in both premenopausal and postmenopausal 
women with breast cancer (11). The American cancer society cancer prevention study 
followed almost 500,000 women from 1982 until 1998 and found a significant (p<.001) 
positive association between BMI and breast cancer mortality (11). While there are 
many ways in which an obese environment can lead to tumorigenesis such as 
increased leptin, reduced adiponectin, increased adipose tissue macrophage (ATM)  
infiltration, increased estrogen production, and vascular endothelial growth factor 
(VEGF) release (13-19) Figure 1. ; the primary focus will be on the deleterious effects 
of hyperinsulinemia and insulin-like growth factors signaling.  
OBESITY INDUCED INSULIN RESISTANCE  
Obesity induces enhanced intracellular oncogenic signaling through creating an 
extracellular environment in which mitogenic stimuli are prevalent. One method in which 
adipocytes can contribute to excess growth stimuli is through the acquisition of insulin-
resistant adipocytes (14). Insulin resistance is defined as a reduced response to insulin-
stimulated glucose uptake in the liver, muscle and adipose tissue and is hypothesized to 
be a result of chronic systemic low-grade inflammation commonly seen in obesity (20, 
21).  In obesity, insulin resistance is ultimately obtained through a defect in insulin 
receptor activity through mediators such as c-Jun NH2-terminal kinase (JNK 1 and 2), 
inhibitor of kappa β kinase (IKK), extracellular related kinase 1 & 2, (ERK 1/2), mitogen-
activated protein kinase (MAPK), and insulin receptor substrate (IRS) 1 & 2 (20-22). 
Moreover, insulin resistance signaling mediators in obesity are hypothesized to be 
downstream effectors from various metabolites and signals which include increased free 




sources, diacylglycerols (DAGs), reactive oxygen species (ROS), endoplasmic 
reticulum (ER) stress, tumor necrosis factor-α (TNF-α), and glucose (21).  
INSULIN, IGF-1 & CANCER PROGRESSION 
Insulin resistance has been associated with an increased risk of breast, colorectal, liver, 
and pancreatic cancer (15, 16, 23, 24). Moreover, the insulin receptor (INSR), Insulin-
like growth factor receptor (IGF-1R), and the downstream adapter protein insulin 
receptor substrate-1 (IRS-1) have been associated with decreased survival and 
treatment resistance in breast cancers (23, 24). There are varied mechanisms in which 
insulin resistance is associated with an increased cancer risk and worse prognosis, 
including hyperinsulinemia, increased bioactive IGF-1, circulating sex hormones, and 
ROS due to hyperglycemia (21, 23, 24). Both insulin and insulin-like growth factors 
(IGFs) result in similar downstream signals for increased cellular survival, proliferation, 
and differentiation (16, 21, 23, 24). In muscle and liver, the insulin receptor is primarily 
responsible for the translocation of the GLUT 4 receptor to the plasma membrane for 
glucose influx in response to an increase in plasma glucose and insulin (21, 24). 
However, there are isoforms of insulin receptors that respond to both insulin-like growth 
factor II (IGF-II) and insulin that result in signaling for proliferation and growth in cells 
(21, 24, 25). The INSR and IGF-1R receptor also can hybridize as one dimeric structure 
to respond to insulin and IGF-1 (23, 24). Thus, obesity can mediate tumorigenic effects 






Figure 1. Obese Adipose Tissue 
The lean adipose tissue, depicted on the left consists of a majority of M2 adipose tissue 
macrophages (ATM). These are associated with secreted anti-inflammatory cytokines 
such as IL-10, IL-4, IL-13, IL-33. Also, these adipocytes secrete signaling molecules 
such as peroxisome proliferative activated receptor (PPAR ) and STAT 6 which favor 
oxidative metabolism. The lean adipose tissue also have Th2 T cells, eosinophils, and 
regulatory T cells (Tregs). Conversely obese adipose tissue favors glycolytic 
metabolism by activation of glycolytic metabolism regulators such as lactate 
dehydrogenase (LDH), STAT 1, and hypoxia-inducible factor 1 – α (HIF-α). The M1 
macrophages secrete cytokines such as TNF-α, IL-6, IL-1β, and other inflammatory 
molecules. The obese adipose tissue also contains more Th17 and Th1 lymphocytes as 
well as fewer eosinophils and more neutrophils. This image was obtained from Castoldi, 




1.3 The IGF-1 System  
 
BASIC STRUCTURE AND FUNCTION OF INSR & IGF-1R  
The IGF signaling cascaded is an important and complex sequence of signals that are 
primarily responsible for cell proliferation and survival (26). There have been many 
studies showing the essentiality of IGF-1R in tumor development as well as both an 
overexpression of the IGF-1R/INSR hybrid and the downstream adapter protein, IRS-1 
in tumors (26-30). The IGF signaling pathway is initiated primarily by three ligands, 
insulin, IGF-1, and IGF-2 (26). However, there are a few more members IGF family 
such as the ligand antimicrobial peptide LL-37, the orphan insulin-related-receptor-
receptor (IRR), the insulin-like growth factor-1 – insulin hybrid receptor (26). The main 
receptor tyrosine kinases involved are the insulin receptor (INSR), insulin-like growth 
factor-1 receptor (IGF-1R), and insulin-like growth factor-2 receptor (IGF-2R). The 
insulin receptor itself has two spliced isoforms: INSRA and INSRB (27). The INSRA 
isoform contains exon 11 and responds to mainly insulin stimulation, while the INSRB 
form lacks exon 11, is activated by IGF-II, and is associated with various cancers (27). 
Both the INSR and IGF-1R share up to 84% identity in the tyrosine intracellular domains 
(26). Moreover, there is a complexity of signaling networks in which the IGF-1R 
“crosstalk’s” with other RTKs such as the epidermal growth factor receptor (EGFR), G-
protein coupled receptor (GPCR), and the INSR by transactivating the INSR tyrosine 
kinase domains (26). The receptors are composed of both an extracellular glycosylated 
α subunit and an intracellular β subunit (26). The IGF-1R begins as Pro-IGF-1R or a 
preformed αβ chain that is activated by glycosylation and proteolysis (26) that 




2. The majority of the receptor is composed of the β chain, which consist of an 
extracellular domain, transmembrane domain, juxtamembrane domain, and an 
intracellular tyrosine kinase domain (26, 27). These subunits, such as the α subunit 
consist of 710 amino acids separated by a cysteine-rich domain, which is the primary 
ligand-binding region for both IGF-1R and INSR (26). The beta subunit of the IGF-1R 
contains a 196 amino acid extracellular domain, a 926 amino acid transmembrane 
domain, and an intracellular domain that contains three different regions which include a 
juxtamembrane domain, a tyrosine kinase domain, and a carboxy-end terminal tail (26).  
The juxtamembrane contains residues necessary for IGF-1R internalization, while the 
tyrosine kinase domain contains three essential tyrosine residues that are necessary for 
activation of the receptor (26, 27). The structure and conformation of the activation loop 
in the tyrosine kinase domain of the receptor prevents any ATP binding and acts as an 
autoinhibitory mechanism (26, 27). Due to the location of the activation loop within the 
domain, the tyrosine residues located near the loop are extremely important for the 
receptor activation.  
IGF-1R SIGNALING & REGULATION  
Ligand binding by IGF-1/2 causes the tyrosine 1135 to become trans- phosphorylated 
by adjacent dimers in the activation loop of the IGF-1R (26, 27). This phosphorylating 
event continues down the tyrosine kinase domain where tyrosine autophosphorylation 
attracts certain adapter proteins (26, 27). In particular, tyrosine 950 in the 
juxtamembrane domain seems to be the major tyrosine residue in which Shc and IRS 
adapter proteins are attracted (26). The tyrosine phosphorylating events provide signals 




domains (26, 27). One of the fastest arriving adapter proteins is the insulin receptor 
substrate (IRS), which contains a PTB domain (26). The IRS proteins also have c- 
terminus end that interacts with SH2 domain-containing proteins such as the p85 
catalytic subunit of Phosphoinositol- 3 kinase (PI3K) and growth factor receptor-bound 
protein -2 (Grb2) (26, 27). Another adapter protein that responds to tyrosine 
phosphorylation of IGF-1R is the Shc (SH2 containing protein) class of proteins (26, 27). 
Shc and IRS family of proteins all consist of PTB domains at the N- terminus along with 
an SH2 domain at the C terminus and ultimately lead to recruitment and subsequent 
signaling molecules that lead to tumorigenesis (26).  
PI3K-AKT AXIS  
One mechanism by which IGF-1R leads to tumorigenesis and survival is through the 
Phosphatidylinositol- 3-kinase (PI3K) pathway Figure 3. The PI3K genes, PI3KCA, 
PI3KCB, and PI3KD, are often mutated in many cancers including breast cancer (31). 
The regulatory subunit, p85, and the catalytic subunit, p110, make up the PI3K complex 
(26, 32). PI3K’s main function is the production phosphatidylinositol ( 3,4,5) 
trisphosphate  (PIP3) from and phosphatidylinositol (4,5) biphosphate (PIP2) that is 
formed through the phosphorylation of PIP2 at the 3 ‘ OH position  (26, 31). 
Phosphorylated tyrosines recruit adapter proteins such as IRS and Shc that bind to 
downstream effector molecules (26, 27). IRS-1, for example, can bind to a subunit of 
PI3K, p85 (26). The activation  p110 from p85 results from an alleviation of inhibition in 
the catalytic domain of p110 (26). PI3K’s phospholipid product PIP3 can recruit 
(pleckstrin homology) PH domain-containing proteins such as phosphoinositide-




membrane via PIP3, PDK can phosphorylate Akt at threonine 308 and allow it to signal 
to downstream targets that are involved in survival and proliferation (26, 27). Once Akt 
is membrane-bound and activated by either serine 473 or threonine 308 
phosphorylation, it can target pro-survival and growth proteins (26, 27). Akt carries out 
its pro-survival signaling by inhibiting apoptotic proteins such as Bad, BAX, and caspase 
9 (26). Also, it inhibits glycogen synthase kinase-3 β (GSK-3β)  and forkhead box 
transcription factors (FOXO) (26, 31). Akt activates a major regulator in protein 
synthesis and G0 to G1 cell cycle transition, mechanistic target of rapamycin complex 1 
(mTORC1) (26, 31). Activation of mTORC1 by Akt is mediated through Akt 
phosphorylation and inhibition of the tuberous sclerosis complex 2 (TSC2)  (31). Both 
TSC 1 & 2 have been described as tumor suppressors due to their inhibitory role in 
mTORC1 activation through their properties as GTPase activating proteins (GAPs) (31). 
For mTORC1 to be activated, there must be ample bound GTP to Ras homolog 
enriched in brain (Rheb), which is a small GTPase that controls the activation of 
mTORC1 (33). Thus, TSC 1 & 2 inhibit mTORC1 activation through the hydrolysis of 
GTP, resulting in Rheb inhibition (33). Ultimately, mTORC1 leads to cell cycle 
progression, lipogenic metabolic programming, protein translation, and survival resulting 
in tumor progression.  
MAP KINASE CASCADE  
A second way in which IGF-1R can facilitate in carcinogenesis is through the mitogen-
activated protein kinase (MAPK) signaling cascade Figure 3  (26). Once 
phosphorylated, intracellular tyrosine residues can attract src homology containing 




phosphorylated tyrosine’s through its SH2 domains and subsequent interaction with 
effector molecules can be made possible by its SH3 domains which interact with 
proline-rich motifs present in effector proteins such as sons of sevenless (SOS) (26, 27, 
31). SOS is a guanine nucleotide exchange factor that aids in the release of GDP from 
small GTPases such as Ras (26, 27). Once GDP is release from Ras, GTP can bind 
and result in an activated conformation in the protein (26, 27). A product of Ras is the 
serine/threonine kinase, Raf (26, 27). Upon activation, Raf can participate in a 
phosphorylating cascade that travels down until it reaches the nucleus where various 
transcription factors facilitate cell cycle progression and cell migration (26, 27). The 
phosphorylation cascade begins with Raf’s phosphorylation of MAPK (MEK), which 
phosphorylate the MAPK sub-proteins extracellular related kinase (ERK) 1 and 2 (26, 
31). Both ERK 1 & 2 can localize to the nucleus or target cytosolic proteins (26, 31). The 
target proteins of ERK 1&2 are involved in cell-cycle progression and ultimately 
proliferation as well as cell migration through spindle formation (26, 31). Some specific 
downstream targets of MAPK and ERK that relate to tumor progression are cyclin D1, 
along with its respected cyclin-dependent kinase, which results in the phosphorylation of 
the tumor suppressor protein retinoblastoma (pRB) (26, 31). Phosphorylation of pRB 
results in histone acetyl transferase recruitment and E2F activation, which controls  G1 






















Figure 2. Insulin-like Growth Factor Receptor  
Insulin-like growth factor receptor structure. There are four known sites for the post-
translational modifications of phosphorylation, sumoylation, and ubiquitination. The N-
terminus region is the extracellular portion in the alpha chain region. The alpha chain 
contains two domains, L1 and L2 separated by a cysteine-rich domain. The two dimers 




membrane and contains an essential motif for receptor internalization. The tyrosine 
kinase domain has essential tyrosine residues for phosphorylation Y 1131, Y1135, 
Y1136. The c- terminal region spans 100 amino acids and plays a regulatory role in the 
receptor activation/deactivation. Some of the adapter proteins that respond to tyrosine 
phosphorylation are Grb, p85, SHP2, and PI3K all of which bind to Y1316. Some other 
adapter proteins such as IRS-1, Shc, CrkII, and CrKL bind to Y950 closer to the cellular 
membrane. This image was obtained from (26, 31). 
 
 
Figure 3. RTK Downstream Signalling 
The signaling cascade upon tyrosine kinase autophosphorylation of the IGF-1R. SH2 
domain-containing adapter protein responds to phosphorylated tyrosine residues and 
phosphorylates other adapter proteins like growth factor receptor-bound protein -2  
(Grb2) and sons of sevenless (SOS) which can activate downstream mitogenic 
signaling such as RAS-RAF-MEK- ERK leading to cell proliferation and growth. The 
insulin receptor substrate (IRS) adapter protein can also bind from its phosphotyrosine 




kinase leading to lipid signaling PIP2 to PIP3 and Akt activation for a variety of pro-
survival and proliferation effects.  
1.4 Fatty Acid Synthase  
 
 BASIC STRUCTURE AND FUNCTION 
Fatty acids are an essential part of every living organism. The biosynthesis of fatty acids 
for membranes aid in cell division and signaling and is an important biological process 
that is ubiquitously expressed in all living tissues. The primary enzyme responsible for 
the biosynthesis of lipids or de novo lipogenesis (DNL) is the fatty acid synthase 
enzyme (FASN) (34-36).  FASN is classified as a multifunctional protein and thus is 
responsible for not only endogenously creating long-chain saturated fatty acids, but also 
as an energy storage enzyme in which it takes excessive carbon influx and stores it as 
triglycerides in adipose tissue for subsequent β-oxidation (34, 37, 38).  FASN is a 
homodimeric enzyme in which two ~250 kDa monomers are composed of 7 catalytic 
enzymes with an acyl carrier protein (ACP)  that contains a 4’ phosphopantetheine 
prosthetic group covalently attached to the serine hydroxyl of the ACP (34, 36). The N-
terminus contains 3 catalytic domains, while the C-terminus contains 4  (34). FASN is 
structured in a head to tail fashion, where the three domains in the N-terminus and the 
four domains in the C-terminus are separated by 600 residues (34). The subunits, 
ranging from the N-terminus region to the C-terminus tail are β- ketoacyl synthase (KS), 
acetyl/malonyl transacylase (AT/MT), β-keto acyl reductase (KR), 3-hydroxy acyl ACP 
dehydratase (DH), Enoyl Reductase (ER), along with two additional  Acyl Carrier 
Protein (ACP), and Thioesterase (TE) groups (34, 36). 




One of the more important functions of FASN is the production of the 16-carbon 
saturated fatty acyl chain, palmitic acid. FASN forms palmitic acid via de novo 
lipogenesis (DNL) from the two substrates acetyl coenzyme A (acetyl- CoA) and 
malonyl coenzyme A (malonyl Co-A), while using nicotinamide adenine dinucleotide 
phosphate (NADPH) as a reducing agent (34, 37, 39, 40). Since, DNL occurs outside 
the mitochondria and in the cytosol, acetyl-CoA must transport out of the mitochondrial 
membrane in a different form. Excessive amounts of pyruvate fed into the tricarboxylic 
acid cycle (TCA), leads to the production of high amounts of citrate produced from the 
combination of oxaloacetate and acetyl-CoA by the enzyme citrate synthase (37, 39). 
Citrate is subsequently transferred out of the mitochondrial matrix and converted back 
into acetyl-CoA and oxaloacetate via  ATP citrate lyase (ACYL) (37, 41, 42). Acetyl-
CoA, in a carboxylation reaction using carboxybiotin to donate a CO2, is converted to 
malonyl-CoA from the enzyme Acetyl-CoA carboxylase (ACC) (36, 37). NADPH is 
available both from the conversion of malate back to pyruvate via the malic acid enzyme 
as well as from the pentose phosphate pathway (34, 37).  Once the conditions are met, 
the synthesis of palmitic acid can commence. The complex synthesis reaction that leads 
to the production of palmitic acid was first discovered in Escherichia Coli (E. Coli) as the 
type 2 fatty acid synthase enzyme (34, 36).  The series of reactions add two carbons 
per cycle and repeats seven times until a final palmitic acid product is formed. The 
condensation reaction uses two carbons from the acetate in the Acetyl-CoA as a primer, 
while malonyl-CoA acts as the chain extending donator (34, 36). Using its three 
carbons, malonyl-CoA donates two carbons to the acetate moiety, releasing the third 




Acetyl -CoA + 7 malonyl- CoA + 14 NADPH + 14 H+ → Palmitic Acid + 7 CO2 + 14 
NAD+ + 6 H2O 
Figure 4. de novo Lipogenesis  
The FASN enzyme has two main sites for the covalent attachment of acyl carbons. The 
sites include the thiol on the cysteine of the β-ketoacyl synthase (KS) and the Acyl 
Carrier Protein (ACP) with the prosthetic 4’ phosphopantetheine group (34, 36).  The 
series of condensation and decarboxylative reactions, which are represented in Figure 
4. ,  are carried out by four main reactions: condensation, reduction, dehydration, and a 
final reduction (34, 36). The first step to the biosynthesis of palmitic acid, termed the 
substrate loading phase (34, 36), involves the recycling of the CoA thioester group from 
both the acetyl and malonyl moieties by the acetyl/malonyl transacylase (AT/MT) 
enzymes (34, 36). The acetate moiety covalently attaches to the thiol of the cysteine on 
the KS domain, while the malonate moiety is attached to the thiol of the 
4’phosphopantetheine (36). The next set of reactions are a part of the chain elongation 
phase. In the initial step, β-ketoacyl synthase (KS) catalyzes the condensation of the 
two substrates to ultimately form acetoacetyl-ACP and resulting in a release of CO2 
(34). Next, in an NADPH dependent reaction, Β-ketoacyl reductase (KR) reduces 
acetoacetyl-ACP to the β-hydroxy butyryl-ACP (34). Β-hydroxy butyryl-ACP undergoes 
a dehydration reaction with the aid of the β-hydroxy acyl dehydrase enzyme (34). The 
β-hydroxy butyryl -ACP group loses water, ultimately forming a double carbon bond and 
subsequently forms butenyl-ACP (34). The following reaction is another NADPH 
dependent reduction reaction carried out by the enoyl reductase (ER) enzyme, 
ultimately resulting in the formation of butyryl-ACP (34). The KS domain subsequently 




to ACP being able to accept another transfer of carbons from malonate moiety for 
further chain elongation (34). This malonate loading and sequential transfer of its two 
carbons to the acetyl group continues until palmitoyl-ACP is formed. With the use of the 
water that was previously released by the dehydration reaction, the thioesterase 
enzyme cleaves and releases the S-ACP group from palmitoyl-ACP resulting in a 
palmitate product.  
1.5 FASN: Recent Advances and Clinical Implications 
FASN is not highly expressed in many healthy tissues with exception to cycling 
endometrium, lactating breast, liver, and adipose tissue (37, 39, 40, 42). The saturated 
fatty acid products of FASN, palmitate (C16:0), myristate (C14:0), and stearate are 
essential for membrane fluidity as well as post-translational modifications of proteins 
and subsequent membrane localization via palmitoylation and myristylation (34, 39). 
Also, the long-chain fatty acids stearate and palmitate can be used for further acyl chain 
elongation to produce very-long-chain fatty acids, which are used as membrane lipids 
such as sphingolipids, ceramides, and glycolipids all of which are essential for normal 
cell division and growth (34). Numerous studies have shown the upregulation of FASN 
in cancers including ones conducted by Cui et al., (43)  that recorded an increase in 
FASN by immunohistochemistry analysis in 50 patients with breast cancer without an 
increase in neighboring non-tumorigenic tissue in the breast (43).  In the same study, 
there was an increase in apoptosis in both triple-negative and ER-positive breast cancer 
cell lines, and apoptosis was accompanied by a concomitant increase in NADPH, 
highlighting a new potential mechanism of FASN induced cancer progression (43). 




preclinical setting, however, early FASN inhibitors resulted in off-target toxicities and 
side effects. A FASN inhibitor currently in clinical trials, TVB-2640, has shown promise 
with very good patient tolerance (44-46). Also, another FASN inhibitor is emerging as a 
promising treatment, Fasnall, targets the keto-acyl reductase domain in FASN (47). 
Moreover, both the FASN inhibitors Fasnall and C75 attenuated growth and proliferation 
in HER2 positive cell lines along with ER-positive cell lines expressing HER2 (47, 48). 
Moreover, the effect on FASN inhibition on endocrine dependent breast cancer has also 
been demonstrated (49). Apoptosis in breast cancer cells in response to FASN 
inhibition has been well established previously, however, precise mechanisms have not 
been elucidated and hold great importance for increasing efficacy of FASN inhibitors as 
well as highlight potential combinatorial treatment options. There have been studies 
elucidating the connection to the FASN product palmitate and receptor tyrosine kinase 
function, such as the localization of the c-MET receptor (50). Palmitate, FASN’s product, 
undergoes S-palmitoylation by a family of 23 known zDHHC palmitoyl acyltransferase 
enzymes resulting in an increased affinity for membranes, more efficient folding and 
stability, increased protein to protein interactions (51). Moreover, a study by Kristin 
Runkle et al., (52) illustrated that the inhibition of zDHHC 20 palmitoyl transferase 
enzymes increases signaling in EGFR (52). Conversely, inhibition of FASN using 
orlistat, resulted in a ubiquitination and attenuation of signaling of mutant EGFR in non-
small cell lung cancer (NSLC), further highlighting the complexity and need for studying 
the connection between FASN and receptor tyrosine kinase signaling in cancer (53).  
Moreover, studies have illustrated that mutating essential cysteine residues for 




membrane as well as FASN inhibition resulting in a decreased total IGF-1R expression 
(55). Thus, FASN has multiple approaches in contributing to tumor progression, but the 
research is lacking in the mechanisms behind the connection to FASN modulation and 
RTK signalling.  
Chapter 2: Insulin-like Growth Factor Receptor as a Target of FASN Modulation in 
Obesity Induced Breast Cancer 
 
2.1 Abstract  
INTRODUCTION Breast cancer is among the highest prevalence of cancer-related 
death in post-menopausal women with increases commensurate with body mass index 
(BMI). The long-chain saturated fatty acid products of FASN, such as palmitate, have 
been known to post-translationally modify proteins and receptors and consequently 
result in an increased affinity and localization to the plasma membrane. Currently, the 
localization of the receptor tyrosine kinase, Insulin-like Growth Factor Receptor (IGF-
1R), in response to increased expression of fatty acid synthase is being investigated as 
a mechanism of obesity-induced breast cancer progression. METHODS To visualize the 
localization of the IGF-1R in response to FASN expression, MCF-7 cells were treated 
with a FASN inhibitor and either obese or non-obese sera and subjected to 
immunofluorescence. RESULTS MCF-7 cells treated with TVB-3266 for 24 hours 
resulted in an abrogated membrane localization of IGF-1R. CONCLUSION This study 
provides mechanistic insight into how the expression of FASN could be contributing to 
obesity-induced breast cancer progression through the localization of the IGF-1R. FASN 







Obesity, is a rapidly rising epidemic (56) with a prevalence of up to 34% in the United 
States (57).  Breast cancer is among the highest prevalence of cancer-related death in 
post-menopausal women with increases commensurate with BMI (18, 58). Previous 
studies, including in our lab, have demonstrated an augmented aggression in breast 
cancer when exposed to obese conditions (18, 59, 60). The mechanism behind the 
more aggressive phenotype of breast cancer in obese individuals has become an active 
area of research, however, the precise modes of action remain enigmatic. The obese 
phenotypic characterization is associated with an increased energy storage that results 
in enlarged adipocytes that can become hypoxic and ultimately necrotic resulting in the 
recruitment of macrophages and the formation of “crown-like structure” hallmark of 
obese adipocytes(61, 62). Also, adipocytes can lose their ability to accommodate 
excess lipids resulting in increased adipocyte lipolysis and free fatty acid (FFA) release 
resulting in insulin resistance  (12, 13, 62). There are multiple proposed mechanisms in 
which obesity can lead to enhanced tumorigenesis, such as elevated lipids and lipid 
signaling, inflammation, adipokines, and insulin signaling (62). Both our lab and others 
have recorded an increased FASN expression in response to obese sera in both 
adipocytes and cancer cells such as breast, endometrial, and prostate (37, 39, 62). 
FASN in normal tissues, with exception to lactating breast, cycling endometrium, and 
adipocytes  is not highly expressed due to exogenous dietary fatty acids (FA) being the 
predominant source (37, 39). The lipogenic phenotype of cancer, in which lipids are 
endogenously synthesized from excess intake of glucose, has been well established 




(37, 42, 63). FASN, in an NADPH dependent manner, acts to endogenously 
biosynthesize long-chain fatty acids, store FA in adipocytes for subsequent ß-oxidation, 
and produce phospholipids for membranes (37, 39). The overexpression of FASN in 
tumor types as well as adipocytes has made FASN a possible target for therapy in 
obesity-induced cancer. Some previous FASN targeted inhibitors included, the 
Curelinin, Orlistat, epigallocatechin-3gallate (ECGC), and other flavonoids (41). 
However, early FASN inhibitors were limited in their use as a therapeutic agent for 
cancer patients because they induced cachexia,(64) which is detrimental to cancer 
patients undergoing treatment. Newer, more targeted inhibitors toward FASN have 
shown promise in early clinical studies, and currently the FASN inhibitor, TVB-2640, is 
in phase II of clinical trials for the treatment of multiple cancers including breast 
administered as both monotherapy as well as in combination with paclitaxel (46). There 
are multiple proposed mechanisms of how FASN inhibitors promote cancer cell 
apoptosis including the reduction of palmitate for post-translational protein modifications 
and membrane composition, toxic accumulation of the FASN substrate Malonyl-CoA, 
decreased membrane synthesis, and disruption to lipid rafts. (37, 39-41, 63, 64) . In an 
interesting study utilizing a novel FASN inhibitor, TVB 3567, and tracking tumor 
metabolism by isotopically labelled [U-13C] glucose and [13C] C16:0 palmitate; Daniel 
Benjamin et al. ,  found that 231-MFP and MCF-7 breast cancer cells not only 
decreased the de novo glucose derived palmitate synthesis but cell viability was also 
significantly decreased in response to FASN inhibition (41). Receptor tyrosine kinases, 
such as the Insulin-like growth factor receptor (IGF-1R), are commonly mutated and 




study by Jang et al., (54),  investigated the palmitoylation of membrane proteins and 
their involvement in the localization of growth receptors to the plasma membrane. Jang 
et al. (54), found when the membrane protein flotillin-1 palmitoylation was defected 
using a palmitoylation-deficient cysteine 34 (C34A)  mutant, the co-localization of IGF-
1R from the endoplasmic reticulum to the plasma membrane was inhibited by up to 40% 
(54). The downstream oncogenic signaling cascades of IGF-1R, as well as other 
receptor tyrosine kinases (RTK), involve activation of two major pathways Raf activated 
kinase/ mitogen-activated protein kinase (RAF/MAPK) as well as the 
phosphatidylinositol- 3-kinase/protein kinase B (PI3K/AKT) pathways (26). These 
ultimately lead to downstream signaling such as cellular survival, growth, and 
differentiation (26).  
There have been numerous studies elucidating the effectiveness of FASN inhibitors for 
the treatment of breast cancer, however, there have been few studies illustrating a 
connection to FASN expression and IGF-1R function in breast cancer. Thus, this study 
is investigating FASN as a contributor to breast cancer aggression through the 
localization of the IGF-1R. The results from this study provide insight into a mechanism 
by which obesity promotes a worse prognosis in obese breast cancer patients. 
2.3 Methods  
 
 Antibodies  
 
Rabbit polyclonal antibodies against IGF-1R β ( cat#3027S), p-IGF-1R β tyrosine 
(1150/1151) ( cat#3024) were purchased from Cell Signalling Technology (Danvers, 
MA, USA). For immunofluorescence, FITC conjugated anti-mouse IgG secondary 





Serum was collected from postmenopausal women. BMI was calculated and serum was 
pooled according to the BMI of the patient (non- obese  (Non- OB: 18.5-24.9 kg/m2); 
obese (OB:≥ 30 kg/m2)).  
Cell Culture  
MCF-7 and MDA-MB-231 human breast cancer cell lines were maintained in essential 
minimum essential medium (EMEM) (GIBCO Life Technologies, Grand Island, USA) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.  
Growth Factor and FASN Inhibition Treatment  
The FASN inhibitor, TVB-3166, was acquired from Dr. Andrew Brenner. Human 
recombinant Insulin-like growth factor (IGF-1) was purchased from R&D systems 
(cat#291-61). MCF-7 and MDA-MB-231 cells were treated either with or without IGF-1 
(10nM) for 60 minutes and with TVB-3166 (200 nM) or with the drug vehicle dimethyl 
sulfoxide DMSO  for either 24 or 72 hours and were subsequently subjected to further 
analysis.  
Immunofluorescence  
MCF-7 cells were seeded in complete EMEM supplemented with 10% FBS at a density 
of 10,0000 cells per 8- well chamber slides (Lab-Tek II Chamber Slide System 
cat#152941). Cells were exposed to 2% non-obese and serum-free media (SFM), 2% 
Obese + SFM , 2% Obese + DMSO + SFM , and 2% Obese + TVB-3166 + SFM  for 24, 
48, and 72 hours. Media was removed after respected incubation time and washed with 
1x phosphate-buffered saline (PBS). The cells were then fixed in 4% Formaldehyde in 




serum (Novex Life Technologies, cat#PCN500) blocking buffer solution. After blocking, 
the primary antibody IGF-1R β (cat#3027S) was added overnight at 4C followed by the 
secondary FITC conjugated anti-mouse IgG antibody (Abnova Corporation 
cat#PAB4971). The chamber was then removed, washed three times in 1xPBS and 
mounted in Invitrogen prolong gold antifade reagent with DAPI (Thermo Fisher 
Scientific, cat#P36941). The slides were allowed to dry for 24 hours and then visualized 
using a LEICA confocal microscope at 63X.  
2.4 Results  
 
FASN Expression Results In IGF-1R Localization.  
IGF-1R is upregulated in many cancers and is associated with both drug resistance and 
a poor disease outcome in estrogen receptor-positive breast cancers (28). IGF-1R 
activation by insulin and IGF-1  results in tyrosine phosphorylation and recruitment of 
adapter proteins and downstream oncogenic signaling through RAS-RAF- mitogen-
activated protein kinase (MAPK) and PI3K-Akt  for survival and proliferation (26). 
Moreover,  long-chain fatty acid products of FASN have been previously demonstrated 
to post-translationally modify and stabilize proteins and receptors for enhanced 
oncogenic signaling (54, 66). To visualize the role of  FASN and the localization of the 
IGF-1R to the plasma membrane,  MCF-7 cells were treated with either 2% non-obese 
sera, 2% obese sera, 2% obese sera + DMSO, and 2% obese sera + TVB-3166. The 
slides were fixed and mounted with anti- IGF-1R β (cat#3027) and FITC secondary 
antibody along mounting fluid with DAPI nuclear stain. Subsequent imaging using a 
Leica confocal microscope (63X) resulted in an increased localization of IGF-1R in the 




in a decreased localization (Figure 5 A&B). These results reveal a new potential 
connection to FASN expression and IGF-1R localization in obesity-induced breast 
cancer.  
2.5 Discussion  
 
While the link between obesity and cancer progression is firmly rooted, the specific roles 
that obesity plays in accentuating tumorigenesis are still being elucidated. In the present 
study, we demonstrated a possible link between obesity and increased breast cancer 
aggression through FASN induced IGF-1R localization. We previously recorded an 
increase in FASN expression in cancer cells exposed to 2% obese sera compared to 
cancer cells exposed to 2% non-obese. Also, inhibition of FASN by treatment with TVB-
3166 reduced localization of the IGF-1R to the membrane during both IGF-1 and obese 
sera exposure. Though we did not elucidate a mechanism in which the FASN inhibition 
attenuates localization of the IGF-1R to the membrane, increased amounts of the FASN 
product palmitate could be a contributor. Palmitate, through the zDHHC palmitoyl 
acyltransferase family of enzymes, is known to aid in the affinity of proteins to lipid rafts 
within the plasma membrane (66). There has not been evidence of direct palmitoylation 
of IGF-1R, however, studies have shown other proteins with palmitoylation sites 
cysteine residues that are responsible for the localization of IGF-1R. For example, 
studies by Jang et al., highlight the imperative role of the flotillin-1 membrane protein 
and its palmitoylation for the intracellular transport of IGF-1R (54). The palmitoylation of 
the cysteines on the membrane proteins might explain a possible mechanism in which 
FASN causes the increased localization of the IGF-1R. Moreover, an increase in de 




but have not been attributed as a link between obesity driven cancer aggression. While 
many mechanisms are currently being investigated to understand how the correlation 
occurs, obesity-induced FASN upregulation has been identified as playing a role. Future 
research efforts should try and identify the effect that palmitate has in localization of the 
IGF-1R as well as the effects of this localization on subsequent drug sensitivity and cell 
viability. As our breast cancer patient population becomes increasingly obese, it is of 
utmost need to find novel therapeutics to combat the obesity-induced cancer growth. 
Based on the results, FASN inhibition appears to show promise as a nontoxic, novel 
therapeutic for the treatment of obesity-induced breast cancer.  





Figure 5 A.  
To provide a visualization of the IGF-1 receptor in response to FASN inhibition, MCF-7 
Cells were treated with 2% non-obese sera, 2% obese sera, and 2% obese sera with a 
FASN inhibitor (TVB-3166) for 24 hours. The treated cells were probed for IGF-1β 
(green) followed by the secondary FITC (red) conjugated antibody. The nuclei were 









Figure 5 B  
To visualize the localization of the IGF-1 receptor, MDA-MB-231 cells were pre-treated 
with or without 200nM of TVB-3166 or DMSO for 72 hours and exposed to IGF-1. From 
top to bottom cells were treated with either IGF-1, DMSO + IGF-1, or TVB-3166 +IGF-1.  
IGF-1R was probed for using anti-IGF-1Rβ antibody (green) followed by secondary 
FITC (red) conjugated antibody. The nuclei were stained using DAPI nuclear stain 
(blue). The images were visualized using confocal microscopy.  




In summary, this study provided mechanistic insight as to how obesity contributes to a 
more aggressive breast cancer. The IGF-1R receptor is correlated with breast cancer 
drug resistance as well as aggressiveness, thus its increased localization in response to 
obese sera exposure highlights a potential therapeutic target for treating obese 
individuals with breast cancer. Also, we previously recorded an increase in FASN 
expression when breast cancer cells were exposed to obese sera vs non-obese. The 
use of a FASN inhibitor, TVB-3166, abrogated both the membrane localization and 
phosphorylation of IGF-1R. Moreover, this study found a FASN dependent mechanism 
of breast cancer progression through the localization and activation of the IGF-1R in 
response to obese conditions. Through this study, we have provided both reverse 
translational insight for a mechanism of a drug currently entering clinical trials and a 
potential obesity-targeted therapy for breast cancer patients.  





There are two main questions I would like to answer for future directions from this study. 
Namely, how is the IGF-1R being localized to the membrane in response to FASN and 
obese sera exposure and how is FASN upregulated in obesity? The connection to an 
obese environment and metabolic programming for lipogenesis, such as increasing 
FASN expression is a popular area of research not only for cancer but also for non-
alcoholic fatty liver disease. The mechanisms are still being elucidated as to how FASN 
is transcriptionally controlled. Investigating this mechanism would hold significant 
clinical relevance due to the growing number of cancer therapeutics targeting cancer 
metabolism and in particular its ability to transition to a lipogenic phenotype via 
upregulating FASN expression.  Obesity is associated with both an increase in insulin 
and IGF-1, which both contribute to the activation of Akt and mTORC1. I would like to 
investigate the role of Akt and mTORC1 in lipogenic programming through FASN in 
obesity-induced breast cancer. Studies have shown mTORC1 to stabilize FASN mRNA 
leading to and enhance gene expression of FASN (67). Also, Akt seems to play a 
pivotal role of FASN expression through the SREBP family of transcription factors (68, 
69). A few studies are highlighting the importance of membrane protein localization in 
response to palmitoylation. Granted the IGF-1R does not have any known residues to 
be palmitoylated, there are many membrane proteins with known residues that are 
palmitoylated that are essential for RTK localization and signaling. Flotillin-1 requires 
palmitoylation for function as is associated with IGF-1R membrane localization, 
however, the model has not been tested in breast cancer (54). Moreover, I would like to 
transition into the roles of the flotillin proteins and cancer aggression. There have been 




of invadopodia. The connection between FASN and flotillin proteins is not quite clear 
and still needs further elucidation. However, the contribution of flotillins to breast cancer 
progression is established and is associated with aggressiveness through EMT 
transcription factors such as snail as well as matrix metalloproteases that are 
responsible for the degradation of the extracellular matrix (70-72). Finally, I would like to 
expand on current studies showing FASN as a contributor to drug resistance (53, 73). 
The studies are mainly involved non-small cell lung carcinoma, however, I believe the 
mechanisms could translate over to breast cancer. In summary, my future directions 
involve the investigation of FASN in breast cancer as well as its programming and its 
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